Bottneuro wins final stage of Venture Kick
DBE Spin-Off Bottneuro will be supported by Venture Kick with CHF 150’000.
The world population is aging more quickly than ever before, which is why more and more people have Alzheimer's disease. The earlier the disease is diagnosed, the better the chances of slowing down its progression. Bottneuro AG, located at the Novartis Campus and under the leadership of Dr. Bekim Osmani, uses novel positron emission tomography (PET) scanners to detect Alzheimer's before the first symptoms even appear. In a second step, based on the 3D-PET scan data, individual headsets are 3D-printed, allowing patient-specific electrode montages and, therefore, electrical stimulations of the affected regions only.
Venture Kick will support Bottneuro with CHF 150'000 to advance its technology and prepare the clinical trials.